Centre Hospitalier De Cholet — Clinical Trial Site

68 Registered trials

36 Currently recruiting

Organisation

Centre Hospitalier De Cholet

Location

Cholet, France

Identifier

ORG-100044180

Address

1 Rue De Marengo, 49300, France

Departments

1810 :Rhumatologie
1810: Rheumatology
2014:Cardiology
2303: Service d'Anesthésie
2343: Service de Médecine Vasculaire
49
Cardiologie
Département de Cardiologie
Gastro-enterology
Gastroenterology
Hepato-gastro-enterology and Oncology
Hépatogastroentérologie
Hepatogastroenterology
Intensive Care Unit
Médecine Vasculaire
Medical Oncology
Medical Oncology Department
NA
Oncologia
ONCOLOGIE
Oncologie médicale
Oncologist
Oncologue
Oncology
Pneumologie
Pneumology
Réanimation
Rhumatologie
Service d'hépatologie - gastrologie - entérologie et oncologie
service d'oncologie
Service d'oncologie médicale
Service d'Urgence
Service de Cardiologie
Service de Pneumologie
Service onco-hématologie

Clinical trials at this site (68)

Search interface

SALVOVAR trial: A pragmatic randomized phase III trial to assess the utility of adjusting chemotherapy dose & dosing schedule with the SALVa… Recruiting

2023-508260-30-01 Patients with poor prognostic OVARian cancers based on 5 2024-07-30
Treatment of microstellite stable metastatic colorectal cancer presenting high immune infiltrate with chemotherapy (XELOX or FOLFOX Bevacizu… Recruiting

2024-515788-73-00 MICROSATELLITE STABLE (MSS) METASTATIC COLORECTAL CANCE 4 2024-07-30
RIVACAST - RIVAroxaban versus low-molecular weight heparin in patients with lower limb trauma requiring brace or CASTing Recruiting

2023-509905-62-00 Lower limb trauma requiring immobilisation 5 2024-07-19
Phase III study to evaluate the effect of balcinrenone/dapagliflozin in patients with heart failure and impaired kidney function Recruiting

2023-508162-15-00 Chronic HF and comorbid impairment of kidney function w 5 2024-07-12
PRODIGE 87 FOXTROT II : Personalising and refining neo-adjuvant chemotherapy in locally advanced but resectable colon cancer in the elderly … Recruiting

2023-505214-23-00 colon carcinoma 5 2024-06-07
Gut microbiome intervention with EXL01 in combination with nivolumab and FOLFOX as first-line treatment for patients with PD-L1 CPS ≥5 metas… Recruiting

2023-506753-38-00 metastatic gastric adenocarcinoma 4 2024-04-16
A Randomized, Multicenter, Placebo-controlled, Phase 3 study to Evaluate the Efficacy and Safety of HER2/neu Peptide GLSI-100 (GP2 + GM-CSF)… Recruiting

2023-504323-25-01 breast cancer 5 2024-03-19
Weaning protocol for high-flow nasal oxygen therapy in the ICU - Multicenter randomized controlled trial. HiFloWEAN Recruiting

2023-504366-36-00 de novo acute respiratory failure 5 2024-02-17
Capsaicin 179 mg patch versus oral Duloxetine in patients with chemotherapy-induced peripheral neuropathy: a phase 3 randomized multicentric… Recruiting

2023-504618-31-00 Chemotherapy induced peripheral neuropathy (CIPN) 5 2023-10-20
Best Antithrombotic Therapy in patients with acute Venous ThromboEmbolism while taking antiplatelets: the BAT-VTE Recruiting

2022-500974-33-00 acute venous thromboembolism event 5 2023-08-12
Oxaliplatin ± nivolumab in combination with trifluridine/tipiracil or 5- fluorouracile ± nivolumab in frail patients with advanced, recurren… Recruiting

2024-512999-35-00 Patients with HER 2 negative locally advanced, recurren 4 2023-06-23
Maintenance Pembrolizumab at Usual or Low doSE in non-squamous lung cancer: a non-inferiority study Recruiting

2023-503481-23-00 Maintenance treatment in metastatic non-squamous lung c 5 2023-03-20
Evaluation of an initial treatment with bevacizumab in combination with chemotherapy and then in combination with niraparib in maintenance i… Recruiting

2023-504166-37-00 Advanced ovarian, tubal or peritoneal cancer. 4 2022-02-01
An open-label randomized trial COmparing staNdard of care versus Treat to target with telemonitoRing and patient education in patients with … Recruiting

2023-507256-76-00 Ulcerative colitis 6 2020-01-14
Ribociclib in combination with endocrine therapy in patients with “estrogen receptor-positive and HER2-negative” breast cancer with high ris… Ended

2023-508827-10-00 Patients with primary operable stage II, grade 2 or 3, 4 2025-10-13
A multi-center, open-label extension study of subcutaneous secukinumab to evaluate the long-term safety and tolerability in polymyalgia rheu… Ended

2023-508077-85-00 Polymyalgia Rheumatica 5 2024-11-19
Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-… Ended

2024-513540-29-00 Breast Cancer 5 2024-11-07
A study of sigvotatug vedotin versus docetaxel in previously treated non-small cell lung cancer (Be6A Lung-01) Ended

2023-503827-25-01 Non-Small Cell Lung Cancer (NSCLC) 5 2024-02-16
Safety and efficacy analysis of an antibody associated with a chemotherapy for patients with a triple negative metastatic breast cancer. Ended

2022-502369-10-00 Triple negative metastatic breast cancer 5 2023-10-02
A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine-Based Therapy Ended

2022-501024-20-00 ER+/HER2- Early Breast Cancer 5 2023-07-25
IFCT-2201 ADAPTABLE A study evaluating the combination of paclitaxel-bevacizumab ± atezolizumab in patients with advanced lung cancer progre… Ended

2022-502103-30-00 advanced non-squamous non-small cell lung cancer 4 2023-04-25
PRODIGE 81-FFCD 2101-TRIPLET: Study evaluating the benefit of adding Ipilimumab to the combination of Atezolizumab and Bevacizumab in patien… Ended

2022-501217-31-00 Hepatocellular carcinoma 10 2023-03-09
Reduction of hormone therapy duration in women with hormonesensitive breast cancer at very low risk of metastatic recurrence Ended

2024-514480-26-00 Post-menopausal women with localized luminal A breast c 4 2022-10-12
A research study to find out whether a medicine called inclisiran helps to prevent cardiovascular death, heart attacks or strokes in people … Ended

2024-510735-21-00 Atherosclerotic cardiovascular disease (ASCVD) 5 2021-11-26